> Figure 2. Proportion of patients who received a particular medication either at baseline or at 6 months of follow-up. Only about one third of patients taking angiotensin-converting enzyme (ACE) inhibitors (30% in the enhanced access group and 32% in the usual care group) achieved the target dose recommended in the Agency for Health Care Policy and Research guideline for treatment of congestive heart failure. (2) The change in use of digoxin between study groups was statistically significant (P=0.02); the change in ACE inhibitor use was not.

From "Enhanced Access to Primary Care for Patients with Congestive Heart Failure" Effective Clinical Practice, September/October 1999. 2:201-209.

Article Text
Home

Figure 2. Proportion of patients who received a particular medication either at baseline or at 6 months of follow-up. Only about one third of patients taking angiotensin-converting enzyme (ACE) inhibitors (30% in the enhanced access group and 32% in the usual care group) achieved the target dose recommended in the Agency for Health Care Policy and Research guideline for treatment of congestive heart failure. (2) The change in use of digoxin between study groups was statistically significant (P=0.02); the change in ACE inhibitor use was not.

Figure 2. Proportion of patients who received a particular medication either at baseline or at 6 months of follow-up. Only about one third of patients taking angiotensin-converting enzyme (ACE) inhibitors (30% in the enhanced access group and 32% in the usual care group) achieved the target dose recommended in the Agency for Health Care Policy and Research guideline for treatment of congestive heart failure. (2) The change in use of digoxin between study groups was statistically significant (P=0.02); the change in ACE inhibitor use was not.

>